Claims
- 1. A therapeutic method for treating sickle cell anemia in a patient having such condition which comprises administering to said patient a therapeutically effective amount of a drug capable of inhibiting the formation of irreversible sickle cells selected from the group consisting of 1,4-dihydropyridines, .beta.-phenethylamines, benzothiazepines, ethylenediamines and diaryl alkyl amines.
- 2. A method as claimed in claim 1 wherein said 1,4-dihydropyridine is selected from the group consisting of nitrendipine, nifedipine, nimodipine, nisoldipine and niludipine.
- 3. A method as claimed in claim 1 wherein said .beta.-phenethylamine is tiapamil or verapamil.
- 4. A method as claimed in claim 1 wherein said benzothiazepine is diltiazem.
- 5. A method as claimed in claim 1 wherein said ethylenediamine is bepridil.
- 6. A method as claimed in claim 1 wherein said diaryl alkyl amine is selected from the group consisting of lidoflazine, prenylamine, fendiline, terodiline, cinnarizine and flunarizine.
- 7. A method as claimed in claim 1 wherein said route of administration is parenteral.
- 8. A therapeutic method for treating sickle cell anemia in a patient having such condition which comprising administering to said patient a therapeutically effective amount of a compound capable of inhibiting the formation of irreversible sickle cells which compound is selected from the group consisting of nitrendipine, nifedipine and verapamil.
- 9. A therapeutic method for treating sickle cell anemia in a patient having such condition which comprises administration to said patient of from 0.1 to 100 mg/Kg of patient body weight per day of a 1,4-dihydropyridine capable of inhibiting the formation of irreversible sickle cells.
- 10. A method as claimed in claim 9 wherein said 1,4-dihydropyridine is nitrendipine or nifedipine.
BACKGROUND OF THE INVENTION
This application is a Continuation-In-Part of co-pending U.S. application Ser. No. 510,593, filed July 5, 1983, now abandoned, the disclosure of which is incorporated herein by reference.
1. Field of the Invention
Normal red blood cells have a biconcave shape and are easily deformable. Red blood cells are oxygenated in the lungs and travel through blood vessels to the capillary bed where oxygen delivery to the tissues is carried out. During this oxygenation-deoxygenation cycle, because they are deformable, normal red blood cells are able to pass through capillary channels which are narrower than the red blood cells.
In 1910, abnormal red blood cells in the peripheral blood of a patient with unexplained anemia led to the first description of what is now called "sickle cell anemia" (SCA). It was observed that the deformed cells had thin, elongated, sickle and crescent-shaped forms and lacked normal deformability.
It has now been established that SCA and related diseases, e.g., thalassemia, are types of hemoglobinopathy caused by abnormal hemoglobin due to a genetic disorder of hemoglobin. When normal hemoglobin becomes deoxygenated, the manner in which its four peptide chains are folded becomes different from that of oxyhemoblogin. In SCA and thalassemia, the abnormal hemoglobin polymerizes upon deoxygenation, causing aggregation of the molecules and distortion of the cell into its characteristic sickle shape, having decreased deformability. This decreased deformability can produce pathological manifestations which include painful vaso-occlusive crisis, bone infarct, cellulitis, osteomyelitis, or anemia (splenic infarct).
The majority of red blood cells of SCA patients become sickled when deoxygenated and return to the original unsickled shape when reoxygenated, i.e., sickling is generally reversible. However, there are a certain number of permanently deformed cells in the circulation of such patients (from 2 to 30 percent) which maintain a sickle shape even after prolonged oxygenation. These abnormal cells are called "irreversibly sickled-cells" (ISC) and because of this lack of deformability, these cells are sequestered and destroyed in reticuloendothelial organs such as the spleen and liver. This is considered to be the major cause for the anemic condition of the patients.
2. Description of the Prior Art
Because SCA and thalassemia involve polymerization of abnormal hemoglobin, most investigators have been searching for compounds which can bind with hemoglobin and inhibit polymerization of deoxyhemoglobin. Urea and cyanate have been proposed as antisickling compounds on the basis of results which indicate that these compounds inhibit the formation of deoxyhemoglobin polymer in vitro. Because the concentration of hemoglobin within the red blood cells is about 5 mM, the concentration of a compound which binds to the hemoglobin to inhibit polymerization must be on the same order of concentration or higher. Clinical tests of urea and cyanate have shown that various side effects prohibit the use of those compounds.
Proc. Natl. Acad. Sci., 77, 2955-2959 (1980), describes a new concept of anti-sickling compounds, e.g., cetiedil, which inhibit sickling based upon interaction with red blood cell membranes. E.J. Pharm., 75, 121-125 (1981), describes the use of nonneuroleptic forms of anti-psychotics in anti-sickling therapy. Proc. Natl. Acad. Sci., 72, 4153-4156 (1975) and 73, 3288-3292 (1976) describes the use of sulfhydril reagents in anti-sickling therapy. U.S. Pat. No. 4,137,309 describes normalizing the deformability of sickle-cells by administration of organophosphates. The Anticalcium and Erythrocyte Membrane Effects of Zinc, and their Potential Value in the Treatment of Sickle Cell Anemia, Brewer and Kruckeberg, Department of Human Genetics, University of Michigan Medical School, Ann Arbor, Mich. (1979), pages 195-202, proposes treating SCA with zinc sulfate or zinc acetate. Brewer et al set forth various theories as to why the zinc may work. One theory is increase in erythrocyte oxygen affinity. Another is inhibition of polymerization of deoxyhemoglobin, such as indicated for urea and cyanate mentioned supra. Brewer et al also speculate about zinc having some effect on the flux of Ca.sup.+2 through the membrane of red blood cells. The flux of Ca.sup.+2 through the membrane of red blood cells is extensively discussed in Rosa et al, "Development of Therapeutic Agents for Sickle Cell Disease", Inserm Symposium No. 9, Institut National de la Sante et de la Recherche Medicale, North-Holland Publishing Company (1979).
On the other hand, Brewer et al at page 196 specifically state that the "decrease in sickle cell pain crisis frequency . . . must be viewed with caution in view of the strong placebo effects possible". In other words, Brewer et al are proposing that zinc may only treat the symptoms, i.e. alleviate the sickle cell pain crisis, rather than treat the sickling phenomenon. In particular, Brewer et al at pages 198-199 point out that disagreement exists as to the role of Ca.sup.+2 in the formation of sickled blood cells, and it has been observed that ISC's can be induced to form in the absence of Ca.sup.+2. Also, it is mentioned that the zinc compounds cause a copper deficiency (Brewer et al at page 196).
Obviously, there has been a long felt need for a compound to treat SCA. Because hemoglobinopathy is caused by a genetic defect, SCA patients will have to undergo a therapeutic regimen for extended periods of time. Therefore, the toxicity and other undesirable side effects of such drugs in long-term administration will be critical in the treatment of such patients. Compounds such as urea, cyanates, sulfhydrils and organophosphates suffer the disadvantage of toxic side effects, and zinc causes a copper deficiency.
Neither the articles or the patent discussed above disclose or suggest that drugs capable of blocking the calcium .sup.+2 channel in and out of muscle cells can be used to treat hemoglobinopathy. Such Ca.sup.+2 channel blocking drugs have been shown to be safe for long term administration.
Flaim et al, Calcium Blockers, Baltimore-Munich, pages 139, 140, 170-173, 183-187, 196 (1982), discuss many of the Ca.sup.+2 channel blocking drugs of the instant application with particular emphasis on verapamil, nifedipine, and diltiazem. Specifically, Flaim et al at page 140 are concerned with the chronotropic and inotropic effects of these three drugs on the cardiac muscle. The book, Calcium Channel Blocking Agents in the Treatment of Cardiovascular Disorders, edited by Stone and Antman, Futura Publishing Co., (1983) is an anthology of earlier published papers discussing the effects and mechanisms of such Ca.sup.+2 channel blocking drugs on the flux of Ca.sup.+2 in and out of myocardial cells. From Stone and Antman and from Flaim et al it is quite clear that the Ca.sup.+2 channel blocking drugs which they discuss are known for treating heart muscle conditions such as angina. Nowhere do either of these references suggest anything to the person skilled in the art and knowledgable about zinc treatment for SCA that "muscle cell" Ca.sup.+2 blockers would be effective in treating "red blood cell" conditions because the same term "Ca.sup.+2 blockers" is being used in two different ways. Thus, it is to be understood that the term Ca.sup.+2 channel blocking drugs, when used in this specification, is intended to mean those drugs which are capable of blocking the influx and efflux of Ca.sup.+2 through muscle cells.
The present invention is directed to a therapeutic method for treating hemoglobinopathy. The method involves administering to a patient a therapeutically effective amount of a drug capable of blocking the Ca.sup.+2 channel in and out of muscle cells to inhibit the formation of irreversible sickle cells.
The present invention involves the inhibition of formation of irreversibly sickled-cells in hemoglobinopathy by administration of a Ca.sup.+2 channel blocking drug. Ca.sup.+2 channel blocking drugs include 1,4-dihydropyridines, such as nitrendipine, nifedipine, nimodipine, nisoldipine and niludipine. Other Ca.sup.+2 channel blocking drugs include .beta.-phenethylamines such as tiapamil and verapamil; benzothiazepines such as diltiazem; ethylenediamines such as bepridil; and diaryl alkyl amines such as lidoflazine, prenylamine, fendiline, terodiline, cinnarizine and flunarizine.
In the present specification, the expression "diluent or carrier" means a pharmaceutically acceptable nontoxic substance that when mixed with the active ingredient or ingredients renders it suitable for administration. Other pharmaceutically acceptable ingredients such as salts in correct quantities to render the composition isotonic, buffers, surfactants, coloring and flavoring agents, and preservatives can be present. Examples of suitable solid and liquid diluents and carriers are the following: water containing buffering agents which can be rendered isotonic by the addition of glucose or salts; nontoxic organic solvents; such as paraffins, vegetable oils; alcohols; glycols; natural ground rock (for example, kaoline, aluminas, talc or chalk); synthetic rock powders (for example, highly dispersed silica or silicates); and sugars.
Oral administration can be effected utilizing solid and liquid dosage unit forms such as powders, tablets, dragees, capsules, granulations, suspensions, solutions, and the like. Where appropriate, dosage unit formulations for oral administration can be microencapsulated to prolong or sustain the release, as for example, by coating or embedding particulate material in polymers, wax, or the like.
Parenteral administration can be effected utilizing liquid dosage unit forms, such as sterile solutions and suspensions intended for subcutaneous, intramuscular or intravenous injection. These are prepared by suspending or dissolving a measured amount of the compound in a nontoxic diluent or carrier suitable for injection, such as an aqueous or oleaginous medium and sterilizing the suspension or solution. Stabilizers, preservatives, and emulsifiers can also be added.
Generally, the parenteral dosage of the Ca.sup.+2 channel blocking drug in a composition for administration wil be from 0.1 to 10 mg/kg, preferably from 0.1 to 5 mg/kg, of body weight per day, and the oral dosage form will be from 0.1 to 100 mg/kg, preferably 0.5 to 50 mg/kg, of body weight per day.
The procedure used to demonstrate the effectiveness of the Ca.sup.+2 channel blocking drugs in inhibiting the formation of ISC in a patient having sickle-cell anemia is described below.
Red blood cells from patients with SCA were exposed to repeated deoxygenation-reoxygenation cycles for 15 hours at 37 degrees C. Under these conditions, approximately 20 to 30 percent of the red blood cells present formed ISCs. The amount of ISCs formed in the presence of a Ca.sup.+2 channel blocking drug under identical conditions was measured and the amount of inhibition of formation of ISCs determined.
US Referenced Citations (1)
| Number |
Name |
Date |
Kind |
|
4383997 |
Boucher |
May 1983 |
|
Non-Patent Literature Citations (4)
| Entry |
| "Calcium Blockers", edited by Flaim et al., Urban & Schwarzenberg, Baltimore-Munich 1982, pp. 139, 140, 170-173, 183-187 & 196. |
| Ann. Soc. Med. Trop. 1969, 49 z, 205-210. |
| J. Int. Med. Res. (1976) 4, 375-381. |
| "Development of Therapeutic Agent for Sickle Cell Disease", 1979, North-Holland Pub. Co. AM.-N.Y-OX. pp. 7-11 & 195-202. |
Continuation in Parts (1)
|
Number |
Date |
Country |
| Parent |
510593 |
Jul 1983 |
|
Patent Grant
4851404
